M-CPP and Fenfluramine in Cocaine Addicts - 3

This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: December 2002

The purpose of this study is to evaluate predictive value of M-CPP and fenfluramine challenges for outcome.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: M-CPP
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Hospitalization, arrests, jail, employment, psychiataric symptoms

Estimated Enrollment: 0

Ages Eligible for Study:   25 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000314

United States, New York
VA Medical Center
Brooklyn, New York, United States, 11209
Sponsors and Collaborators
Principal Investigator: Laure Buydens-Branchey, M.D. Department of Veterans Affairs
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000314     History of Changes
Other Study ID Numbers: NIDA-09468-3, R01-09468-3
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 19, 2014